{"id":45234,"date":"2025-10-12T06:49:03","date_gmt":"2025-10-12T04:49:03","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/10\/12\/optimizing-post-transplantation-cell-therapies-to-enhance-graft-versus-leukemia-effects-in-hematological-malignancies\/"},"modified":"2025-10-12T06:49:03","modified_gmt":"2025-10-12T04:49:03","slug":"optimizing-post-transplantation-cell-therapies-to-enhance-graft-versus-leukemia-effects-in-hematological-malignancies","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/10\/12\/optimizing-post-transplantation-cell-therapies-to-enhance-graft-versus-leukemia-effects-in-hematological-malignancies\/","title":{"rendered":"Optimizing post-transplantation cell therapies to enhance graft-versus-leukemia effects in hematological malignancies"},"content":{"rendered":"<div>\n<p><b>Curr Opin Immunol<\/b>. 2025 Oct 10;97:102675. doi: 10.1016\/j.coi.2025.102675. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Allogeneic hematopoietic cell transplantation (HCT) can cure patients with high-risk hematologic malignancies. Donor T and natural killer (NK) cells contribute to graft-versus-leukemia (GVL) effects that provide relapse protection. Post-HCT relapses often represent inadequate GVL, but alloreactive lymphocytes that confer GVL may also cause graft-versus-host-disease (GVHD). Here, we review recent developments to selectively augment GVL while minimizing GVHD. Insights into the unique mechanisms of post-HCT T cell dysfunction highlight interventions to enhance GVL-mediating T cells. Early clinical data suggest that adoptive transfer of engineered donor T cells, expressing either transgenic T cell receptors specific for minor histocompatibility antigens presented exclusively on recipient hematopoietic cells or chimeric antigen receptors binding surface proteins on malignant cells, can mitigate post-HCT relapse. NK cells, key GVL mediators after haploidentical HCT, can be induced into a highly functional memory-like state and administered to HCT recipients to enhance GVL. These innovations promise much-needed improvements in post-HCT outcomes.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41075386\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=8900118&amp;ff=20251012004902&amp;v=2.18.0.post9+e462414\">41075386<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1016\/j.coi.2025.102675\">10.1016\/j.coi.2025.102675<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Curr Opin Immunol. 2025 Oct 10;97:102675. doi: 10.1016\/j.coi.2025.102675. Online ahead of print. ABSTRACT Allogeneic hematopoietic cell transplantation (HCT) can cure patients with high-risk hematologic malignancies. Donor T and natural killer (NK) cells contribute to graft-versus-leukemia (GVL) effects that provide relapse protection. Post-HCT relapses often represent inadequate GVL, but alloreactive lymphocytes that confer GVL may also &#8230; <a title=\"Optimizing post-transplantation cell therapies to enhance graft-versus-leukemia effects in hematological malignancies\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/10\/12\/optimizing-post-transplantation-cell-therapies-to-enhance-graft-versus-leukemia-effects-in-hematological-malignancies\/\" aria-label=\"Read more about Optimizing post-transplantation cell therapies to enhance graft-versus-leukemia effects in hematological malignancies\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[59,42],"tags":[],"class_list":["post-45234","post","type-post","status-publish","format-standard","hentry","category-current-opinion-in-immunology","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/45234","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=45234"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/45234\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=45234"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=45234"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=45234"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}